Olema Pharmaceuticals Inc (OLMA) Stock Price, Quote & News

Company Profile

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivota...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 651 3316

Website: olema.com

Address:

780 Brannan Street, San Francisco, United States

theBigDollarski Oct. 21 at 11:59 AM

$OLMA i was waiting for a pullback and got it..I'm in

0 · Reply

DaBullRunner Oct. 20 at 8:29 PM

BYND there it goes… TOLD YOU👇🤑💰🤑💰🤑 RVP adding this before the crowd arrives 🚨🚨🚨 Adding with the CEO 🚢📦📦📦 This could be the next OPEN I’m telling you And I got in this EARLY $CHNR $JWEL $OLMA $OSRH $GIFT let’s get it

0 · Reply

Gabu Oct. 20 at 5:40 PM

$OLMA Market is discounting it and favoring Roche but the data is very positive.

0 · Reply

mikelet Oct. 20 at 1:28 PM

$OLMA I understand results are good for 120mg, isn't it?

2 · Reply

OpenOutcrier Oct. 20 at 12:23 PM

$OLMA (-30.1% pre) 15.5‑Month Median PFS — Olema Oncology's 120 mg palazestrant + ribociclib supports Phase 3 OPERA-02 https://ooc.bz/l/81151

0 · Reply

JarvisFlow Oct. 20 at 11:58 AM

HC Wainwright & Co. updates rating for Olema Pharmaceuticals ( $OLMA ) to Buy, target set at 28.

0 · Reply

justiceforb_85 Oct. 19 at 4:03 AM

$OLMA palezsatrant likely best-in-class and active in ESR1-WT patients.

1 · Reply

microeone Oct. 18 at 4:37 PM

$OLMA good data release albeit phase 1/2… continue to show pala might be best in class

1 · Reply

Quantumup Oct. 8 at 3:46 PM

Guggenheim🏁 $OLMA Buy/$20 $NVS $PFE $RHHBY Guggenheim said in it initiation report:

0 · Reply

FormFour Oct. 5 at 3:33 PM

$OLMA Healthcare technology. Testing key support. Volume pattern shows distribution. Growth concerns persisting.

0 · Reply

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Oct 2, 2025, 4:30 PM EDT - 23 days ago

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 2, 2025, 7:00 AM EDT - 7 weeks ago

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

PFE

Aug 20, 2025, 4:30 PM EDT - 2 months ago

Olema Oncology to Participate in Upcoming Investor Conferences

Aug 11, 2025, 4:01 PM EDT - 2 months ago

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

May 28, 2025, 7:00 AM EDT - 5 months ago

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

May 13, 2025, 4:01 PM EDT - 5 months ago

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

Apr 25, 2025, 1:00 PM EDT - 6 months ago

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

Apr 8, 2025, 4:25 PM EDT - 7 months ago

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Mar 25, 2025, 4:31 PM EDT - 7 months ago

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Mar 18, 2025, 4:01 PM EDT - 7 months ago

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 18, 2025, 7:00 AM EST - 8 months ago

Olema Oncology Appoints Shawnte M. Mitchell, J.D.

Jan 2, 2025, 7:00 AM EST - 10 months ago

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 7:46 AM EST - 11 months ago

Top 3 Health Care Stocks That May Explode In Q4

SLN

Dec 10, 2024, 7:00 AM EST - 11 months ago

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Dec 9, 2024, 7:00 AM EST - 11 months ago

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Nov 25, 2024, 5:30 PM EST - 11 months ago

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Nov 12, 2024, 4:01 PM EST - 1 year ago

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 6, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 28, 2024, 7:03 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in June

May 15, 2024, 7:01 AM EDT - 1 year ago

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

May 8, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

May 1, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in May

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

Mar 11, 2024, 4:03 PM EDT - 1 year ago

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 7:03 AM EST - 1 year ago

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Jan 8, 2024, 8:12 AM EST - 1 year ago

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Jan 3, 2024, 8:29 AM EST - 1 year ago

Olema Pharmaceuticals: Oral SERD Developer With Interesting Data

Jan 2, 2024, 4:01 PM EST - 1 year ago

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 12:27 PM EST - 2 years ago

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Nov 28, 2023, 5:10 PM EST - 2 years ago

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

Nov 28, 2023, 11:52 AM EST - 2 years ago

Olema Pharmaceuticals: Advancing On Multiple Fronts

Nov 7, 2023, 4:02 PM EST - 2 years ago

Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 1, 2023, 4:27 PM EDT - 2 years ago

Olema Oncology to Participate in Upcoming Investor Conferences in November

Oct 22, 2023, 2:55 AM EDT - 2 years ago

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

Oct 17, 2023, 7:01 AM EDT - 2 years ago

Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors

Oct 16, 2023, 7:02 AM EDT - 2 years ago

Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

Oct 12, 2023, 7:01 AM EDT - 2 years ago

Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

Sep 20, 2023, 7:29 AM EDT - 2 years ago

Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 3:20 PM EDT - 2 years ago

Olema: Two-Pronged Approach To Treat Breast Cancer Patients

Sep 5, 2023, 7:30 AM EDT - 2 years ago

Olema Oncology Announces Combined Financing for Up to $180 Million

Aug 8, 2023, 4:03 PM EDT - 2 years ago

Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference

May 30, 2023, 4:30 PM EDT - 2 years ago

Olema Oncology to Present at the 2023 Jefferies Healthcare Conference

May 19, 2023, 4:30 PM EDT - 2 years ago

Olema Oncology: Best Contrarian Oncology Play For 2023

May 11, 2023, 8:43 AM EDT - 2 years ago

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

theBigDollarski Oct. 21 at 11:59 AM

$OLMA i was waiting for a pullback and got it..I'm in

0 · Reply

DaBullRunner Oct. 20 at 8:29 PM

0 · Reply

Gabu Oct. 20 at 5:40 PM

$OLMA Market is discounting it and favoring Roche but the data is very positive.

0 · Reply

mikelet Oct. 20 at 1:28 PM

$OLMA I understand results are good for 120mg, isn't it?

2 · Reply

OpenOutcrier Oct. 20 at 12:23 PM

$OLMA (-30.1% pre) 15.5‑Month Median PFS — Olema Oncology's 120 mg palazestrant + ribociclib supports Phase 3 OPERA-02 https://ooc.bz/l/81151

0 · Reply

JarvisFlow Oct. 20 at 11:58 AM

HC Wainwright & Co. updates rating for Olema Pharmaceuticals ( $OLMA ) to Buy, target set at 28.

0 · Reply

justiceforb_85 Oct. 19 at 4:03 AM

$OLMA palezsatrant likely best-in-class and active in ESR1-WT patients.

1 · Reply

microeone Oct. 18 at 4:37 PM

$OLMA good data release albeit phase 1/2… continue to show pala might be best in class

1 · Reply

Quantumup Oct. 8 at 3:46 PM

Guggenheim🏁 $OLMA Buy/$20 $NVS $PFE $RHHBY Guggenheim said in it initiation report:

0 · Reply

FormFour Oct. 5 at 3:33 PM

$OLMA Healthcare technology. Testing key support. Volume pattern shows distribution. Growth concerns persisting.

0 · Reply

elmono Oct. 2 at 3:00 PM

$OLMA high vol up…low vol down…typical accumulation pattern

0 · Reply

SweepCastApp Oct. 2 at 11:10 AM

$OLMA: Unusual Options Activity Alerted CALL flow observed 221x contracts at Strike price of $12 Exp on 11/21/2025 with Premium of $31K and showing BULLISH Sentiment

0 · Reply

DARKP00L Oct. 1 at 5:33 PM

$OLMA momentum building! Stock attracting attention, could be a mover!

0 · Reply

GottaWearShades Oct. 1 at 5:15 PM

$OLMA yep. hope you held on.

0 · Reply

EvCe Oct. 1 at 3:38 PM

$OLMA congrats to everyone! 🦾 ets keep it up! 🚀

0 · Reply

DarthGoat Sep. 30 at 5:06 PM

$OLMA OOOOUUUTTT +27% All calls in real time.

0 · Reply

Jacoz Sep. 26 at 6:05 PM

$ATYR $OLMA is a better investment at the moment.

0 · Reply

Filvul Sep. 18 at 3:11 PM

$OLMA nicee

0 · Reply

Filvul Sep. 15 at 10:20 PM

$OLMA

0 · Reply

ZacksResearch Sep. 12 at 2:40 PM

$OLMA surges 46.5% so far in September — what's driving the rally? A new collaboration announcement with $PFE for OLMA's palazestrant in a phase Ib/II study for metastatic breast cancer is propelling the stock higher. This marks their second partnership, highlighting strong potential in the oncology space. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2750842/olma-stock-soars-47-in-september-so-far-on-second-pfe-deal?cid=sm-stocktwits-2-2750842-body-12192&ADID=SYND_STOCKTWITS_TWEET_2_2750842_BODY_12192

0 · Reply

ZacksResearch Sep. 12 at 1:40 PM

$OLMA ripping higher — up 47% in September on fresh momentum. The driver? A second Pfizer collaboration tied to its lead breast cancer product candidate, palazestrant. Full breakdown here 👉 https://www.zacks.com/stock/news/2750842/olma-stock-soars-47-in-september-so-far-on-second-pfe-deal?cid=sm-stocktwits-2-2750842-teaser-12191&ADID=SYND_STOCKTWITS_TWEET_2_2750842_TEASER_12191

0 · Reply

Market Cap	555.25M
Revenue (ttm)	0.00
Net Income (ttm)	-129.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.01

Volume	1,137,000
Avg Vol	1,235,788
Day's Range	N/A - N/A
Shares Out	68.63M
Stochastic %K	31%
Beta	2.08
Analysts	Strong Sell
Price Target	$24.38